Recruiting Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations NCT06160752 Conditions Acrocephalosyndactylia, Adenocarcinoma, Bone Diseases, +24 more Locations University of California San Francisco (UCSF) — San Francisco, California, United States Massachusetts General Hospital — Boston, Massachusetts, United States The Ohio State University — Columbus, Ohio, United States The University of Texas MD Anderson Cancer Center — Houston, Texas, United States View Trial Details
Not Yet Recruiting AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer NCT07619313 Conditions Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Carcinoma, +18 more Locations UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States View Trial Details
Active, Not Recruiting Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma NCT06178588 Conditions Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +11 more Locations University of Kansas Cancer Center — Kansas City, Kansas, United States View Trial Details
